Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165477 · ClinicalTrials.gov registry record · Phase 2
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT00165477: Completed Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Dana-Farber Cancer Institute.
NCT00165477 is a Phase 2 study of Glioblastoma and Gliosarcoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 23 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165477, a Phase 2 study of Glioblastoma and Gliosarcoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
\- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG lenalidomide
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00165477 record still lists
NCT00165477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT00165477 reports a single indexed study location in Massachusetts, Virginia.
Frequently Asked Questions
What is clinical trial NCT00165477 about?
NCT00165477 is a clinical study titled "Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme". \- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
What is the current status of trial NCT00165477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2005-09. Estimated completion is 2009-07.
What conditions does trial NCT00165477 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Malignant Gliomas.
What interventions are being tested in trial NCT00165477?
The interventions under investigation include: Radiation (RADIATION), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00165477?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165477 being conducted?
This trial has 4 study locations across Massachusetts, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00165477's enrollment target sits among peer trials
23 143rd of 199 higher than 57 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia